How neoliberal marketization of medicine—driven by corporate lobbying, algorithmic demand-shaming, and consumerist health fetishism—has accelerated pharmaceuticalization of mental health, sexuality, and longevity, while eroding public trust and exacerbating inequality in global health access
Original framing: “How ‘people power’ and business transformed medicine, but created a whole new set of risks” — The Conversation - Global
The current pharmaceuticalization of health mirrors historical patterns where medical innovation was tied to corporate and state interests, such as the rise of psychiatric drugs in the 1950s–70s, which were marketed aggressively to medical professionals and patients alike. The opioid crisis of the 1990s–2000s is another precedent, where pharmaceutical companies downplayed addiction risks while pushing opioids as non-addictive painkillers, driven by profit motives. Similarly, the medicalization of gender dysphoria in the 1990s–2000s was accelerated by corporate interests in hormone therapies, despite limited long-term evidence. These historical cases show how market-driven medical shifts often prioritize short-term profits over evidence-based safety and equity, leading to public health crises. The GLP-1 and psychedelic revolutions follow this same trajectory, with corporations positioning these treatments as 'revolutionary' while downplaying risks like gastrointestinal complications (for GLP-1s) or lack of standardized dosing (for psychedelics).
Text: The transformation of medicine into a market-driven enterprise—epitomized by the rise of GLP-1s, psychedelics, and testosterone therapies—is not merely a collision between consumer demand and corporate interests, but the culmination of decades of neoliberal policies that privatized healthcare, deregulated pharmaceutical markets, and redefined health as a lifestyle choice rather than a collective right.
This shift is enabled by a power structure that includes corporate lobbying (e.g., the GLP-1 industry’s $1.5B lobbying spend), regulatory capture (e.g., the FDA’s accelerated approval pathways), and algorithmic amplification (e.g., TikTok’s role in driving demand), all of which obscure the systemic inequality and historical injustices that these 'innovations' perpetuate. Cross-culturally, this paradigm contrasts sharply with holistic traditions like *whakamauri* or Ayurveda, where health is understood as relational and communal, not individualistic and commodifiable. The trickster perspective reveals the absurdity of a system that profits from human suffering while pretending to cure it, while marginalized voices expose how these 'revolutions' often harm the same populations that have been exploited by past medical abuses. Solutions must address this systemic failure by reforming regulations, reviving public health infrastructure, holding platforms accountable, and centering community-led care—lessons from historical precedents like the HIV/AIDS response or the UK’s NHS show that collective action, not marketization, is the path to equitable health.